Methylthioninium chloride Proveblue – EPAR summary for the public (2011)

Government Record · European Medicines Agency (EMA), Committee for Medicinal Products for Human Use · May 6, 2011

European Medicines Agency (EMA), 2011-05-06: EMA public assessment summary for Methylthioninium chloride Proveblue, a 5 mg/mL injection authorised EU-wide on 6 May 2011 as an antidote for methaemoglobinaemia caused by medicines or chemicals, dosed at 1-2 mg/kg intravenously.

The European Commission granted a marketing authorisation valid throughout the European Union for Methylthioninium chloride Proveblue on 6 May 2011.

2-3

European Medicines Agency (EMA), 2011-05-06: EMA public assessment summary for Methylthioninium chloride Proveblue, a 5 mg/mL injection authorised EU-wide on 6 May 2011 as an antidote for methaemoglobinaemia caused by medicines or chemicals, dosed at 1-2 mg/kg intravenously. C6 France/EU – approval record. Applicant/holder: Provepharm (Marseille, France). EU marketing authorisation 6 May 2011, procedure EMEA/H/C/002108, described by EMA as a 'hybrid medicine' referencing Methylthioninium Chloride Injection USP 1% w/v. Indication: antidote to symptoms of methaemoglobinaemia caused by certain medicines or chemicals, adults and children of all ages. Dose: 1-2 mg/kg IV over five minutes for adults and children over 3 months; 0.3-0.5 mg/kg for infants 3 months or younger. Conflict/funding: EU regulatory document, no authors' conflicts. This is the single most important European approval document for methylene blue as a licensed medicine. Also filed as MTP-42 (claims C6, C7). Study type: regulatory record.